DE60033857D1 - Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität - Google Patents

Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität

Info

Publication number
DE60033857D1
DE60033857D1 DE60033857T DE60033857T DE60033857D1 DE 60033857 D1 DE60033857 D1 DE 60033857D1 DE 60033857 T DE60033857 T DE 60033857T DE 60033857 T DE60033857 T DE 60033857T DE 60033857 D1 DE60033857 D1 DE 60033857D1
Authority
DE
Germany
Prior art keywords
oxy
urea
phenyl
represent
antitumor activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033857T
Other languages
English (en)
Other versions
DE60033857T2 (de
Inventor
Kazuo Kubo
Yasunari Fujiwara
Toshiyuki Isoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of DE60033857D1 publication Critical patent/DE60033857D1/de
Application granted granted Critical
Publication of DE60033857T2 publication Critical patent/DE60033857T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
DE60033857T 1999-01-22 2000-01-20 Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität Expired - Lifetime DE60033857T2 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP1485899 1999-01-22
JP1485899 1999-01-22
JP2669199 1999-02-03
JP2669199 1999-02-03
JP14249399 1999-05-21
JP14249399 1999-05-21
JP25362499 1999-09-07
JP25362499 1999-09-07

Publications (2)

Publication Number Publication Date
DE60033857D1 true DE60033857D1 (de) 2007-04-19
DE60033857T2 DE60033857T2 (de) 2007-10-25

Family

ID=27456291

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60006216T Expired - Lifetime DE60006216T2 (de) 1999-01-22 2000-01-20 Chinolinderivate und chinazolinderivate
DE60033857T Expired - Lifetime DE60033857T2 (de) 1999-01-22 2000-01-20 Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60006216T Expired - Lifetime DE60006216T2 (de) 1999-01-22 2000-01-20 Chinolinderivate und chinazolinderivate

Country Status (20)

Country Link
US (3) US6797823B1 (de)
EP (2) EP1153920B1 (de)
JP (2) JP3519368B2 (de)
KR (1) KR100787254B1 (de)
CN (1) CN1183114C (de)
AT (2) ATE253051T1 (de)
AU (1) AU771504B2 (de)
BR (1) BR0007656A (de)
CA (1) CA2361057C (de)
DE (2) DE60006216T2 (de)
ES (2) ES2208261T3 (de)
HK (1) HK1043792A1 (de)
HU (1) HU230789B1 (de)
IL (2) IL144461A0 (de)
NO (1) NO321295B1 (de)
NZ (1) NZ513006A (de)
PL (2) PL206627B1 (de)
TR (1) TR200102090T2 (de)
TW (1) TWI229667B (de)
WO (1) WO2000043366A1 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1140840B1 (de) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
NZ513006A (en) * 1999-01-22 2003-10-31 Kirin Brewery Quinoline derivatives and quinazoline derivatives
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
GB0029015D0 (en) 2000-11-28 2001-01-10 Univ London Medical device
PL209822B1 (pl) * 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
CN100415720C (zh) 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
WO2003008388A1 (fr) * 2001-07-19 2003-01-30 Kirin Beer Kabushiki Kaisha Cristal en i de n-?2-chloro-4-?(6,7-dimethoxy-4-quinazolinyl)oxy?phenyl?-n'-propyluree et methode de production du cristal
WO2003033472A1 (fr) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
ATE549329T1 (de) 2002-02-01 2012-03-15 Astrazeneca Ab Chinazoline verbindungen
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003235838A1 (en) * 2002-05-01 2003-11-17 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
WO2003101444A1 (en) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1604665B1 (de) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase-hemmer
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
AU2013204031B2 (en) * 2003-09-26 2016-10-27 Exelixis, Inc. c-Met modulators and methods of use
AU2004275842B2 (en) * 2003-09-26 2010-09-02 Exelixis Inc. c-MET modulators and methods of use
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
WO2005051924A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation キナゾリン誘導体及びその製造方法
AU2004309166B2 (en) * 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
EP1827434B1 (de) * 2004-11-30 2014-01-15 Amgen Inc. Chinolin- und chinazolinanaloge und deren verwendung als medikamente zur krebsbehandlung
CN104688697A (zh) * 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
JP5209966B2 (ja) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
CA2622472C (en) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (de) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumormittel gegen multiples myelom
WO2007092854A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
TW200817409A (en) 2006-08-04 2008-04-16 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008044688A1 (fr) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008087736A1 (ja) * 2007-01-19 2008-07-24 Ube Industries, Ltd. アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
US8557853B2 (en) * 2007-02-09 2013-10-15 Allergan, Inc. Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
JP5352476B2 (ja) * 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
WO2009077766A1 (en) * 2007-12-19 2009-06-25 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009089851A1 (en) * 2008-01-17 2009-07-23 Bayer Schering Pharma Aktiengesellschaft Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
AU2009209295A1 (en) * 2008-01-28 2009-08-06 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
RU2010136050A (ru) * 2008-01-29 2012-03-10 Янссен Фармацевтика Нв (Be) 2-аминохинолиновые производные для использования в качестве ингибиторов секретазы (васе)
ES2610989T3 (es) 2008-03-17 2017-05-04 Ambit Biosciences Corporation 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropano-2-ol)isoxazol-3-il)urea como modulador de quinasas RAF en el tratamiento de enfermedades del cáncer
EP2262772B8 (de) * 2008-04-16 2013-03-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Chinolinderivate als axl-kinase-inhibitoren
JP5734193B2 (ja) * 2008-10-14 2015-06-17 クイ ニング 化合物及び使用方法
JP5579619B2 (ja) * 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20210151988A (ko) 2009-01-16 2021-12-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
CA2752421C (en) * 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
CN101671301B (zh) * 2009-05-05 2014-02-26 江苏省药物研究所有限公司 杂环取代的二苯脲类衍生物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
JP5789259B2 (ja) 2010-07-16 2015-10-07 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
KR20210010671A (ko) 2011-02-10 2021-01-27 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102311395B (zh) * 2011-07-05 2014-04-16 张爱华 喹唑啉环取代的二苯脲类衍生物及其用途
CN102432595B (zh) * 2011-09-14 2013-09-25 湖南有色凯铂生物药业有限公司 N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
CN102408418A (zh) * 2011-10-21 2012-04-11 武汉迈德森医药科技有限公司 Tivozanib酸性盐及其制备方法和晶型
JP6051434B2 (ja) 2011-11-14 2016-12-27 イグニタ、インク． ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体
CN102603718B (zh) * 2012-02-08 2014-01-29 武汉凯斯瑞科技有限公司 西地尼布的合成方法
EP2626073A1 (de) 2012-02-13 2013-08-14 Harmonic Pharma Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
US9695184B2 (en) 2013-02-15 2017-07-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP6669499B2 (ja) * 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
EP3825305A1 (de) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Verfahren zur herstellung von lenvatinib
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN108473435A (zh) 2015-10-05 2018-08-31 纽约市哥伦比亚大学理事会 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
CN106496116A (zh) * 2016-10-21 2017-03-15 沈阳药科大学 含双芳基脲结构的喹啉类化合物及其用途
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
CN108239067A (zh) * 2016-12-27 2018-07-03 沈阳药科大学 喹唑啉酮类衍生物及其制备方法和用途
CN109824587A (zh) * 2017-11-23 2019-05-31 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN109553581B (zh) * 2018-09-25 2022-01-25 广州六顺生物科技股份有限公司 取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
JP2020100598A (ja) 2018-12-25 2020-07-02 公益財団法人応用生化学研究所 レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
CN113620873B (zh) * 2020-05-07 2023-12-08 沈阳药科大学 含锌结合基以及喹啉骨架的化合物的制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
CN1158599A (zh) * 1994-09-20 1997-09-03 住友金属工业株式会社 介质陶瓷组成物及其制造方法
US6143764A (en) * 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
NZ513006A (en) * 1999-01-22 2003-10-31 Kirin Brewery Quinoline derivatives and quinazoline derivatives
TWI281915B (en) * 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
PL209822B1 (pl) * 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
WO2003033472A1 (fr) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
AU2003235838A1 (en) * 2002-05-01 2003-11-17 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
ES2294317T3 (es) * 2002-10-21 2008-04-01 Kirin Pharma Kabushiki Kaisha Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina.
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US20040229676A1 (en) * 2003-04-28 2004-11-18 Gerald Duhamel Method of playing a game of chance

Also Published As

Publication number Publication date
BR0007656A (pt) 2001-10-30
CA2361057C (en) 2010-04-06
EP1153920A1 (de) 2001-11-14
HK1043792A1 (en) 2002-09-27
NO321295B1 (no) 2006-04-18
AU3074800A (en) 2000-08-07
HU230789B1 (en) 2018-05-02
CA2361057A1 (en) 2000-07-27
ATE356117T1 (de) 2007-03-15
KR100787254B1 (ko) 2007-12-20
ES2208261T3 (es) 2004-06-16
IL144461A (en) 2007-07-04
TWI229667B (en) 2005-03-21
WO2000043366A1 (fr) 2000-07-27
IL144461A0 (en) 2002-05-23
PL349036A1 (en) 2002-07-01
NO20012617D0 (no) 2001-05-29
NO20012617L (no) 2001-09-14
NZ513006A (en) 2003-10-31
US20040209905A1 (en) 2004-10-21
US7169789B2 (en) 2007-01-30
PL204856B1 (pl) 2010-02-26
ATE253051T1 (de) 2003-11-15
CN1183114C (zh) 2005-01-05
JP2003286263A (ja) 2003-10-10
DE60006216D1 (de) 2003-12-04
JP3519368B2 (ja) 2004-04-12
PL206627B1 (pl) 2010-09-30
US6797823B1 (en) 2004-09-28
TR200102090T2 (tr) 2002-01-21
EP1384712B1 (de) 2007-03-07
EP1384712A1 (de) 2004-01-28
DE60006216T2 (de) 2004-07-15
EP1153920A4 (de) 2002-04-17
HUP0105133A2 (hu) 2002-07-29
HUP0105133A3 (en) 2002-09-30
DE60033857T2 (de) 2007-10-25
EP1153920B1 (de) 2003-10-29
KR20010101857A (ko) 2001-11-15
CN1344254A (zh) 2002-04-10
US20070027318A1 (en) 2007-02-01
AU771504B2 (en) 2004-03-25
ES2281591T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
DE60033857D1 (de) Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
NO20034595L (no) Kinolin- og kinazolinderivater med azolylgruppe
ATE180468T1 (de) Anthranilsäure derivate
DK0769010T3 (da) 2-[1',2',4'-triazol-3'-yloxymethylen]-anilider og deres anvendelse som pesticider
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
DE69010100T2 (de) Pyrimidinyl herbizides Mittel.
IL160874A0 (en) 4-imidazolin-2-one derivatives
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
ATE371661T1 (de) Tumorhemmende derivate von et-743
IL159792A0 (en) Variolin derivatives and pharmaceutical compositions containing the same
DK0490326T3 (da) Astaxanthin-mellemprodukter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KIRIN PHARMA KABUSHIKI KAISHA, SHIBUYA, TOKYO, JP

8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP